A Phase 3 interventional study of CC-5013 plus dexamethasone and Dexamethasone plus Placebo in Multiple Myeloma, sponsored by Celgene. Completed at 69 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-19.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment
To compare the efficacy of oral CC-5013 in combination with oral pulse high-dose dexamethasone to that of placebo and oral high-dose pulse dexamethasone as treatment for subjects with relapsed or refractory multiple myeloma."
3,712 studies on the registry are indexed under Multiple Myeloma; 752 are open to participants now.
This study's enrollment of 351 is above the median of 41 across 2,965 interventional studies indexed under Multiple Myeloma.
Browse Multiple Myeloma studies →Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
First submitted before Celgene became part of Bristol-Myers Squibb.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Arm A: Oral CC-5013 is initiated on Day 1 of Cycle 1 at a dose of 25 mg daily for 21 days every 28 days. Therefore, the subject will take a placebo identical in appearance to the CC-5013 capsule for week 4 of every 28 days. Oral pulse dexamethasone is administered at a dose of 40mg daily on Days 1-4, 9-12, and 17-20 of each 28 day cycle for Cycles 1 through 4. Beginning with Cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg daily for Days 1-4 every 28 days. In addition, oral CC-5013 placebo capsules will be administered for 28 days of every cycle.
Drug: CC-5013 plus dexamethasone
Arm B: Oral pulse dexamethasone is administered at a dose of 40mg daily on Days 1-4, 9-12, and 17-20 of each 28 day cycle for Cycles 1 through 4. Beginning with Cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg daily for Days 1-4 every 28 days. In addition, oral placebo capsules will be administered for 28 days of every cycle.
Drug: Dexamethasone plus Placebo
Drug pages: Lenalidomide · Dexamethasone
25 mg daily for 21 days every 28 days.
Also known as: Revlimid, lenalidomide
Drug page: Dexamethasone
Oral pulse dexamethasone is administered at a dose of 40mg daily on Days 1-4, 9-12, and 17-20 of each 28 day cycle for Cycles 1 through 4. Beginning with Cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg daily for Days 1-4 every 28 days. In addition, oral placebo capsules will be administered for 28 days of every cycle.
Also known as: Dexamethasone, Placebo
Kaplan-Meier Estimate of Time to Tumor Progression (TTP)
Time to progression was calculated as the time from randomization to the first occurrence of disease progression, as determined by a detailed review of all the myeloma response assessment data using the Bladé criteria (Bladé, 1998). Disease progression was also based on bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.
Time frame: From randomization up to cut-off date of 03 August 2005; up to 24 months
Kaplan-Meier Estimate of Time to Tumor Progression (TTP) (Later Cut-off Date of 02 Mar 2008)
Time to progression was calculated as the time from randomization to the first occurrence of disease progression, as determined by a detailed review of all the myeloma response assessment data using the Bladé criteria (Bladé, 1998). Disease progression was also based on bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.
Time frame: From randomization up to cut-off date of 02 March 2008; up to 51 months
Kaplan-Meier Estimate of Overall Survival (OS)
OS was calculated as the time from randomization to death from any cause. OS was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented.
Time frame: Randomization to data cut off of 03 August 2005; up to 24 months
Kaplan-Meier Estimate of Overall Survival (OS) (Later Cut-off Date of 02 March 2008)
OS was calculated as the time from randomization to death from any cause. OS was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented.
Time frame: Randomization to data cut off of 02 March 2008; up to 51 months
Summary of Myeloma Response Rates Based on Best Response Assessment
Complete Response (CR): Disappearance of monoclonal paraprotein and maintained for ≥ 6 weeks . Remission Response (RR):75-99% reduction in the level of the serum monoclonal paraprotein compared to baseline; 90-99% reduction in 24-hr urinary light chain excretion. Partial Response (PR): 50-74% reduction in the level of monoclonal paraprotein compared to baseline; 50-89% reduction in 24-hr urinary light chain excretion. Stable Disease (SD): Criteria for PR or PD have not been met. Plateau Phase: If PR, stable monoclonal paraprotein values (within 25% above or below nadir)/stable soft tissue plasmacytomas maintained for at least 3 months. Progressive Disease (PD): Reappearance of serum or urinary monoclonal paraprotein on immunofixation or electrophoresis on two consecutive occasions at least one week apart. Increase of percentage of plasma cells in bone marrow aspirate or biopsy to ≥ 5%. Development of at least one new lytic bone lesion or soft tissue plasmacytoma.
Time frame: Randomization to 03 August 2005; up to 24 months
Myeloma Response Rates Based on the Reviewers Best Response Assessment (Later Cut-off Date of 02 March 2008)
Complete Response (CR): Disappearance of monoclonal paraprotein and maintained for ≥ 6 weeks . Remission Response (RR):75-99% reduction in the level of the serum monoclonal paraprotein compared to baseline; 90-99% reduction in 24-hr urinary light chain excretion. Partial Response (PR): 50-74% reduction in the level of monoclonal paraprotein compared to baseline; 50-89% reduction in 24-hr urinary light chain excretion. Stable Disease (SD): Criteria for PR or PD have not been met. Plateau Phase: If PR, stable monoclonal paraprotein values (within 25% above or below nadir)/stable soft tissue plasmacytomas maintained for at least 3 months. Progressive Disease (PD): Reappearance of serum or urinary monoclonal paraprotein on immunofixation or electrophoresis on two consecutive occasions at least one week apart. Increase of percentage of plasma cells in bone marrow aspirate or biopsy to ≥ 5%. Development of at least one new lytic bone lesion or soft tissue plasmacytoma.
Time frame: Randomization to data cut-off of 02 Mar 2008; up to 51 months
Number of Participants With Adverse Events (AE)
An AE is any sign, symptom, illness, or diagnosis that appears or worsens during the course of the study. Treatment-emergent AEs (TEAEs) are any AE occurring or worsening on or after the first treatment of the study drug and within 30 days after the last cycle end date of study drug. A serious AE = any AE which results in death; is life-threatening; requires or prolongs existing inpatient hospitalization; results in persistent or significant disability is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE, Version 2.0): Grade 1 = Mild (no limitation in activity or intervention required); Grade 2 = Moderate (some limitation in activity; no/minimal medical intervention required); Grade 3 = Severe (marked limitation in activity; medical intervention required, hospitalization possible); Grade 4 = Life-threatening; Grade 5 = Death.
Time frame: From first dose of study drug through to 30 days after the last dose, until the data cut-off date of 25 June 2013; up to 90 months
Time to First Symptomatic Skeletal-related Event (SRE) (Clinical Need for Radiation or Surgery to Bone)
Time from randomization to the date of the first occurrence of a symptomatic SRE (clinical need for radiotherapy or surgery to bone).
Time frame: Up to unblinding data cut off of 03 August 2005; up to 24 months
Time to First Worsening on the Eastern Cooperative Oncology Group (ECOG) Performance Scale
The time to first worsening of the ECOG performance status was calculated as the time from randomization to the date of the first worsening compared with the last ECOG evaluation obtained prior to randomization. Data were censored at the last date that the participant was known to be unchanged or improved from before randomization for the participants who had not had worsened at the time of the analysis and for the patients who were lost to follow-up before worsening in the ECOG performance status was documented.
Time frame: Randomization to cut off date of 03 August 2005; up to 24 months
Time to First Worsening on the Eastern Cooperative Oncology Group (ECOG) Performance Scale (Later Cut-off Date of 02 March 2008)
The time to first worsening of the ECOG performance status was calculated as the time from randomization to the date of the first worsening compared with the last ECOG evaluation obtained prior to randomization. Data were censored at the last date that the participant was known to be unchanged or improved from before randomization for the participants who had not had worsened at the time of the analysis and for the patients who were lost to follow-up before worsening in the ECOG performance status was documented.
Time frame: Randomization to cut off date of 02 March 2008; up to 51 months
The study was conducted at 55 sites in Australia, Europe, and Israel. Eligible participants were randomized in a 1:1 ratio to: lenalidomide plus oral pulse high-dose dexamethasone or Placebo plus oral pulse high-dose dexamethasone.
| Milestone | Lenalidomide Plus Dexamethasone (Len/Dex) | Placebo Plus Dexamethasone |
|---|---|---|
| Started | 176 | 175 |
| Safety population | 176 | 175 |
| Evaluable population | 175 | 171 |
| Completed | 54 | 19 |
| Not completed | 122 | 156 |
| Withdrew: Adverse event | 18 | 12 |
| Withdrew: Progression of disease | 67 | 122 |
| Withdrew: Lack of therapeutic effect | 1 | 3 |
| Withdrew: Withdrawal by subject | 23 | 8 |
| Withdrew: Death | 11 | 10 |
| Withdrew: Other | 2 | 1 |
| Milestone | Lenalidomide Plus Dexamethasone (Len/Dex) | Placebo Plus Dexamethasone |
|---|---|---|
| Started | 176 | 175 |
| Completed | 21 | 8 |
| Not completed | 155 | 167 |
| Withdrew: Adverse event | 22 | 12 |
| Withdrew: Progression of disease | 92 | 128 |
| Withdrew: Lack of efficacy | 1 | 3 |
| Withdrew: Withdrawal by subject | 24 | 9 |
| Withdrew: Death | 11 | 11 |
| Withdrew: Other | 5 | 4 |
| Milestone | Lenalidomide Plus Dexamethasone (Len/Dex) | Placebo Plus Dexamethasone |
|---|---|---|
| Started | 21 | 8 |
| Completed | 0 | 0 |
| Not completed | 21 | 8 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Other | 12 | 4 |
| Withdrew: Progression of disease | 7 | 3 |
| Withdrew: Withdrawal by subject | 1 | 0 |
Time to progression was calculated as the time from randomization to the first occurrence of disease progression, as determined by a detailed review of all the myeloma response assessment data using the Bladé criteria (Bladé, 1998). Disease progression was also based on bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.
| weeks | Lenalidomide Plus Dexamethasone | Placebo Plus Dexamethasone |
|---|---|---|
| Kaplan-Meier Estimate of Time to Tumor Progression (TTP) | 52.1 (40.9 to NA) | 20.1 (16.6 to 20.7) |
OS was calculated as the time from randomization to death from any cause. OS was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented.
| weeks | Lenalidomide Plus Dexamethasone | Placebo Plus Dexamethasone |
|---|---|---|
| Kaplan-Meier Estimate of Overall Survival (OS) | NA (NA to NA) | NA (71.6 to NA) |
OS was calculated as the time from randomization to death from any cause. OS was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented.
| weeks | Lenalidomide Plus Dexamethasone | Placebo Plus Dexamethasone |
|---|---|---|
| Kaplan-Meier Estimate of Overall Survival (OS) (Later Cut-off Date of 02 March 2008) | 161.9 (129.3 to 201.4) | 133.3 (101.6 to 174.0) |
Complete Response (CR): Disappearance of monoclonal paraprotein and maintained for ≥ 6 weeks . Remission Response (RR):75-99% reduction in the level of the serum monoclonal paraprotein compared to baseline; 90-99% reduction in 24-hr urinary light chain excretion. Partial Response (PR): 50-74% reduction in the level of monoclonal paraprotein compared to baseline; 50-89% reduction in 24-hr urinary light chain excretion. Stable Disease (SD): Criteria for PR or PD have not been met. Plateau Phase: If PR, stable monoclonal paraprotein values (within 25% above or below nadir)/stable soft tissue plasmacytomas maintained for at least 3 months. Progressive Disease (PD): Reappearance of serum or urinary monoclonal paraprotein on immunofixation or electrophoresis on two consecutive occasions at least one week apart. Increase of percentage of plasma cells in bone marrow aspirate or biopsy to ≥ 5%. Development of at least one new lytic bone lesion or soft tissue plasmacytoma.
| percentage of participants | Lenalidomide Plus Dexamethasone | Placebo Plus Dexamethasone |
|---|---|---|
| Complete Response (CR) | 15.3 | 4.0 |
| Partial Response (PR) | 43.8 | 19.4 |
| Stable Disease (SD) | 29.0 | 56.6 |
| Progressive Disease (PD) | 2.8 | 14.3 |
| Not Evaluable (NE) those without response data | 9.1 | 5.7 |
Complete Response (CR): Disappearance of monoclonal paraprotein and maintained for ≥ 6 weeks . Remission Response (RR):75-99% reduction in the level of the serum monoclonal paraprotein compared to baseline; 90-99% reduction in 24-hr urinary light chain excretion. Partial Response (PR): 50-74% reduction in the level of monoclonal paraprotein compared to baseline; 50-89% reduction in 24-hr urinary light chain excretion. Stable Disease (SD): Criteria for PR or PD have not been met. Plateau Phase: If PR, stable monoclonal paraprotein values (within 25% above or below nadir)/stable soft tissue plasmacytomas maintained for at least 3 months. Progressive Disease (PD): Reappearance of serum or urinary monoclonal paraprotein on immunofixation or electrophoresis on two consecutive occasions at least one week apart. Increase of percentage of plasma cells in bone marrow aspirate or biopsy to ≥ 5%. Development of at least one new lytic bone lesion or soft tissue plasmacytoma.
| percentage of participants | Lenalidomide Plus Dexamethasone | Placebo Plus Dexamethasone |
|---|---|---|
| Complete Response (CR) | 17.0 | 4.0 |
| Partial Response (PR) | 42.6 | 19.4 |
| Stable Disease (SD) | 28.4 | 56.6 |
| Progressive Disease (PD) | 3.4 | 14.3 |
| Not Evaluable (NE) those without response data | 8.5 | 5.7 |
An AE is any sign, symptom, illness, or diagnosis that appears or worsens during the course of the study. Treatment-emergent AEs (TEAEs) are any AE occurring or worsening on or after the first treatment of the study drug and within 30 days after the last cycle end date of study drug. A serious AE = any AE which results in death; is life-threatening; requires or prolongs existing inpatient hospitalization; results in persistent or significant disability is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE, Version 2.0): Grade 1 = Mild (no limitation in activity or intervention required); Grade 2 = Moderate (some limitation in activity; no/minimal medical intervention required); Grade 3 = Severe (marked limitation in activity; medical intervention required, hospitalization possible); Grade 4 = Life-threatening; Grade 5 = Death.
| participants | Lenalidomide Plus Dexamethasone | Placebo Plus Dexamethasone |
|---|---|---|
| ≥ 1 Adverse Event | 176 | 175 |
| ≥ 1 Serious Adverse Event | 105 | 79 |
| ≥ 1 AE leading to study drug discontinuation | 46 | 31 |
| ≥ 1 AE leading to dose reduction or interruption | 137 | 100 |
| ≥ 1 Drug-Related Adverse Event | 160 | 151 |
| ≥ 1 Drug-Related Serious Adverse Event | 54 | 30 |
| ≥Death within ≤ 30 days of last dose of study drug | 17 | 20 |
| ≥ 1 Grade 1 or Higher Adverse Event | 176 | 175 |
| ≥ 1 Grade 2 or Higher Adverse Event | 168 | 167 |
| ≥ 1 Grade 3 or Higher Adverse Event | 146 | 119 |
| ≥ 1 Grade 4 or Higher Adverse Event | 52 | 37 |
Time from randomization to the date of the first occurrence of a symptomatic SRE (clinical need for radiotherapy or surgery to bone).
| participants | Lenalidomide Plus Dexamethasone | Placebo Plus Dexamethasone |
|---|---|---|
| Time to First Symptomatic Skeletal-related Event (SRE) (Clinical Need for Radiation or Surgery to Bone) | NA | NA |
Duration of response was calculated for responders and defined as the time from the first observation of a response (e.g., the first time that the appropriate decrease in M-protein level was observed for confirmed responders) to the first documented progression or relapse. Response duration was censored at the last adequate assessment showing evidence of no progression.
| weeks | Lenalidomide Plus Dexamethasone | Placebo Plus Dexamethasone |
|---|---|---|
| Kaplan-Meier Estimate of Duration of Response | 67.6 (42.1 to NA) | 33.3 (22.1 to 51.6) |
Time to progression was calculated as the time from randomization to the first occurrence of disease progression, as determined by a detailed review of all the myeloma response assessment data using the Bladé criteria (Bladé, 1998). Disease progression was also based on bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.
| weeks | Lenalidomide Plus Dexamethasone | Placebo Plus Dexamethasone |
|---|---|---|
| Kaplan-Meier Estimate of Time to Tumor Progression (TTP) (Later Cut-off Date of 02 Mar 2008) | 52.4 (40.9 to 85.6) | 20.1 (16.6 to 20.7) |
The time to first worsening of the ECOG performance status was calculated as the time from randomization to the date of the first worsening compared with the last ECOG evaluation obtained prior to randomization. Data were censored at the last date that the participant was known to be unchanged or improved from before randomization for the participants who had not had worsened at the time of the analysis and for the patients who were lost to follow-up before worsening in the ECOG performance status was documented.
| weeks | Lenalidomide Plus Dexamethasone | Placebo Plus Dexamethasone |
|---|---|---|
| Time to First Worsening on the Eastern Cooperative Oncology Group (ECOG) Performance Scale | 10.1 (8.1 to 16.1) | 12.3 (10.1 to 24.1) |
The time to first worsening of the ECOG performance status was calculated as the time from randomization to the date of the first worsening compared with the last ECOG evaluation obtained prior to randomization. Data were censored at the last date that the participant was known to be unchanged or improved from before randomization for the participants who had not had worsened at the time of the analysis and for the patients who were lost to follow-up before worsening in the ECOG performance status was documented.
| weeks | Lenalidomide Plus Dexamethasone | Placebo Plus Dexamethasone |
|---|---|---|
| Time to First Worsening on the Eastern Cooperative Oncology Group (ECOG) Performance Scale (Later Cut-off Date of 02 March 2008) | 10.1 (8.1 to 16.1) | 12.3 (10.1 to 24.1) |
Duration of response was calculated for responders and defined as the time from the first observation of a response (e.g., the first time that the appropriate decrease in M-protein level was observed for confirmed responders) to the first documented progression or relapse. Response duration was censored at the last adequate assessment showing evidence of no progression.
| weeks | Lenalidomide Plus Dexamethasone | Placebo Plus Dexamethasone |
|---|---|---|
| Kaplan-Meier Estimate of Duration of Response (Cut-off at a Later Date of 03 March 2008) | 68.1 (42.1 to 105.6) | 33.3 (22.1 to 51.6) |
Collected over From first dose of study drug to 30 days after the last visit. Up to 25 Jun 2013 (90 Months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lenalidomide Plus Dexamethasone | — | 105/176 (59.7%) | 175/176 (99.4%) |
| Placebo Plus Dexamethasone | — | 79/175 (45.1%) | 173/175 (98.9%) |
| Event | Lenalidomide Plus Dexamethasone | Placebo Plus Dexamethasone |
|---|---|---|
| PNEUMONIA NOSInfections and infestations | 11/176 | 7/175 |
| DEEP VEIN THROMBOSISVascular disorders | 8/176 | 6/175 |
| RESPIRATORY TRACT INFECTION NOSInfections and infestations | 4/176 | 7/175 |
| PYREXIAGeneral disorders | 6/176 | 7/175 |
| PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders | 7/176 | 2/175 |
| BACK PAINMusculoskeletal and connective tissue disorders | 5/176 | 1/175 |
| BONE PAINMusculoskeletal and connective tissue disorders | 5/176 | 0/175 |
| RENAL FAILURE NOSRenal and urinary disorders | 3/176 | 4/175 |
| UPPER RESPIRATORY TRACT INFECTION NOSInfections and infestations | 4/176 | 0/175 |
| GENERAL PHYSICAL HEALTH DETERIORATIONGeneral disorders | 4/176 | 1/175 |
| Event | Lenalidomide Plus Dexamethasone | Placebo Plus Dexamethasone |
|---|---|---|
| NEUTROPENIABlood and lymphatic system disorders | 71/176 | 17/175 |
| CONSTIPATIONGastrointestinal disorders | 71/176 | 41/175 |
| DIARRHOEA NOSGastrointestinal disorders | 67/176 | 45/175 |
| ASTHENIAGeneral disorders | 64/176 | 46/175 |
| INSOMNIAPsychiatric disorders | 51/176 | 63/175 |
| MUSCLE CRAMPMusculoskeletal and connective tissue disorders | 56/176 | 36/175 |
| ANAEMIABlood and lymphatic system disorders | 52/176 | 49/175 |
| FATIGUEGeneral disorders | 51/176 | 41/175 |
| PYREXIAGeneral disorders | 50/176 | 40/175 |
| WEIGHT DECREASEDInvestigations | 49/176 | 46/175 |
Intent to treat population included all participants who were randomized
| Age, Continuous(years) | Lenalidomide Plus Dexamethasone | Placebo Plus Dexamethasone | Total |
|---|---|---|---|
| Mean | 62.2 ± 10.12 | 62.9 ± 8.80 | 62.6 ± 9.47 |
| Sex: Female, Male(Participants) | Lenalidomide Plus Dexamethasone | Placebo Plus Dexamethasone | Total |
|---|---|---|---|
| Female | 72 | 72 | 144 |
| Male | 104 | 103 | 207 |
| Eastern Cooperative Oncology Group Performance Status(participants) | Lenalidomide Plus Dexamethasone | Placebo Plus Dexamethasone | Total |
|---|---|---|---|
| 0 = (Fully Active) | 78 | 65 | 143 |
| 1 = (Restrictive but Ambulatory) | 72 | 79 | 151 |
| 2 = Ambulatory unable to Work) | 23 | 27 | 50 |
| 3 = (Limited Self-Care) | 0 | 1 | 1 |
| 4 = (Completely Disabled) | 0 | 0 | 0 |
| Missing | 3 | 3 | 6 |
| Number of Prior Anti-Myeloma Therapies(participants) | Lenalidomide Plus Dexamethasone | Placebo Plus Dexamethasone | Total |
|---|---|---|---|
| 1 Prior anti-myeloma therapy | 56 | 57 | 113 |
| 2 or more prior anti-myeloma therapies | 120 | 118 | 238 |
| Time from First Pathological Diagnosis(years) | Lenalidomide Plus Dexamethasone | Placebo Plus Dexamethasone | Total |
|---|---|---|---|
| Median | 3.4 (0.4 to 15.7) | 4.0 (0.3 to 26.6) | 3.7 (0.3 to 26.6) |
| Baseline multiple myeloma stage(participants) | Lenalidomide Plus Dexamethasone | Placebo Plus Dexamethasone | Total |
|---|---|---|---|
| Stage I | 11 | 8 | 19 |
| Stage II | 50 | 57 | 107 |
| Stage III | 115 | 110 | 225 |
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lenalidomide · Dexamethasone